Chugai Pharmaceutical (OTCMKTS:CHGCY) Sees Large Volume Increase – Still a Buy?

Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) saw strong trading volume on Thursday . 639,405 shares were traded during mid-day trading, an increase of 337% from the previous session’s volume of 146,253 shares.The stock last traded at $30.7250 and had previously closed at $30.37.

Wall Street Analysts Forecast Growth

Separately, UBS Group upgraded shares of Chugai Pharmaceutical to a “strong-buy” rating in a report on Tuesday, January 27th. One analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat, the stock has a consensus rating of “Strong Buy”.

Chugai Pharmaceutical Stock Up 4.4%

The firm’s fifty day simple moving average is $27.64 and its two-hundred day simple moving average is $25.02. The firm has a market cap of $105.67 billion, a PE ratio of 36.91 and a beta of 0.63.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings results on Thursday, January 29th. The company reported $0.25 earnings per share (EPS) for the quarter. The business had revenue of $2.25 billion during the quarter. Chugai Pharmaceutical had a return on equity of 22.00% and a net margin of 34.47%. As a group, analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.